Harvest One Expands Satipharms Proprietary Gelpell Product Offerings

Published: April 16, 2020

Harvest One Expands Satipharms Proprietary Gelpell Product Offerings

Harvest One Cannabis Inc. announced its wholly-owned subsidiary Satipharm Ltd. (“Satipharm“) has expanded its product offerings to include two new variants of its unique proprietary CBD Gelpell® product, further enhancing its product portfolio currently on sale in major retailers and pharmacy chains throughout the United Kingdom and Ireland.

Satipharm CBD Advanced Range 
The new Satipharm CBD Advanced range products combine CBD with specifically selected vitamins in the Company’s proprietary Gelpell capsules. The Satipharm CBD Advanced range uses the Company’s patented Gelpell technology to deliver CBD in seamless microbeads that are clinically proven to increase bioavailability. The new Advanced range offers two variants, Focus and Active, designed to address specific consumer’s needs.

Active: Satipharm CBD Advanced Active combines CBD with vitamins A, D, E and K to support general body health and movement while using the proprietary Gelpell® delivery technology

Focus: Satipharm CBD Advanced Focus combines CBD with B vitamins to support mental wellbeing while using the proprietary Gelpell® delivery technology

“A differentiated product offering is key to building a successful brand, as we continue to expand our distribution with major retailers and pharmacy chains throughout the United Kingdom and Ireland,” said Andy Bayfield, Chief Executive Officer of Harvest One. “These innovative new product variations, Active and Focus offer our consumers solutions to specific needs, while leveraging our proven Gelpell® delivery technology.”

Satipharm’s suite of products now includes its flagship product 10mg CBD Gelpell capsule, a high strength 50mg CBD Gelpell capsule and the CBD Advanced range Focus and Active variants. It also includes Satipharm’s range of Lemon & Lime and Cinnamon flavoured CBD oils providing a differentiated market offering to satisfy a larger consumer base.

Satipharm produces a CBD capsule powered by their proprietary Gelpell technology. These capsules take a different approach to other cannabinoid pills currently on the market. Gelpell capsules embed the full spectrum hemp extract CBD in seamless gelatine microspheres. These tiny beads, have been clinically proven to increase the bioavailability of CBD, maximising the delivery of CBD to the body. Manufactured in Switzerland and GMP certified, every Gelpell capsule delivers a consistent dose of cannabinoids.

Satipharm CBD Gelpell capsules have 3.5 times higher bioavailability compared to standard CBD oils. This unique product has undergone Stage I and Stage II clinical trials with the results published in two peer-reviewed international medical journals.

For further details on the clinical trials, please visit our website; https://www.harvestone.com/portfolio/satipharm/#clinical-trials

Harvest One is a global cannabis company that develops and provides innovative lifestyle and wellness products to consumers and patients in regulated markets around the world.

Recent News

View All News Items

Latest Article

Characterizing the Cannabis Experience of the Surreal High Sun Mint Lime Fizz Beverage Using Cognalyzer® EEG

Characterizing the Cannabis Experience of the Surreal High Sun Mint Lime Fizz Beverage Using Cognalyzer® EEG

Herein, Zentrela scientifically characterized the unique cannabis experience created by the SURREAL High Sun Mint Lime Fizz beverage in study subjects. The SURREAL High Sun Mint Lime Fizz beverage contains 10mg of THC, 0mg of CBD, 10mg of CBG, and various non-cannabinoid ingredients such as 4g of sugar and lime juice concentrate, among others.  Through the execution of this study, Zentrela determined the onset time and maximum potency of the psychoactive effects induced by this specific product. Additionally, we quantified significant mood changes potentially associated with the consumption of this beverage.

Read Article